Challenging gene patents.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      The article focuses on the implications of the molecular diagnostics firm Myriad Genetics gene patenting case for gene-based medical technologies and personalized medicine. The case involves a challenge to patents on the BRCA1 and BRCA2 genes, which have been linked to a virulent form of breast and ovarian cancer. Myriad argues that patent protection is necessary to conduct research and bring new products to market. The arguments of other companies against Myriad's patent are cited.